US: Pharmaceuticals
More
-
CV Therapeutics said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
-
A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.
-
Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....
-
It's time to step back from the madness and understand a basic tenet of the markets: Just because something negative happens somewhere, it doesn't mean the sky is falling. In fact, it could be good news for you. Here's why...
-
While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.
-
GlaxoSmithKline's claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing.
-
Gen-Probe has won U.S. approval to sell its Procleix blood test to detect the West Nile virus, a Food and Drug Administration spokeswoman said Friday.
-
A New Jersey jury found on Friday that Merck failed to provide adequate warnings about health risks tied to its withdrawn arthritis drug Vioxx in one case, but decided that it gave adequate warning in another in two suits tried simultaneously.
-
Drugmaker Bayer said Friday that it will cut 6,100 jobs, more than half of them in Europe, as it integrates Schering AG into its health care unit.
-
The fact that Cramer wants you in this sector may confuse you. Yes, we know, this group is responsible for the subprime-lending problem we’re seeing today, but this could end up helping investors.
-
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
-
Federal health advisers recommended Tuesday that the government approve the first bird flu vaccine as a stopgap measure, despite evidence it wouldn't protect most people.
-
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
-
Merck's stock rose before the opening bell Monday after U.S. regulators asked for more data on rival Novartis' diabetes drug, which gives Merck a leg up in the race to launch a new class of diabetes drugs.
-
If the Dems take over the White House in 2008, the diagnostics services sector is where you’ll want to be. That’s because a Democrat in the White House will mean no more buddy-buddy relationship between the government and pharmaceutical companies.
-
Genentech shares traded lower after data from a clinical trial indicated that a lower dosage of the blockbuster cancer drug Avastin was as effective as the standard dose for lung cancer patients.
-
Could room-temperature Byetta heat up sales? Amylin Pharmaceuticals and Eli Lilly announced that the FDA says their diabetes drug Byetta (pronounced buy-ate-uh) doesn't have to be kept in the fridge anymore. Byetta is the twice-a-day stick-pen injectable drug that helps people lower their blood sugar and lose weight
-
Swiss pharmaceutical giant Novartis' plans to launch diabetes treatment Galvus may be dealt a blow by the Food and Drug Administration at the end of the month, market sources told CNBC Europe.
-
Merck said Chief Financial Officer Judy Lewent, 58, plans to retire in July after 17 years in the post.
-
British pharmaceutical company Shire, which makes ADHD drug Adderall XR, said Tuesday it is buying U.S. drug maker New River Pharmaceuticals for approximately $2.6 billion, or $64 per share in cash.